Skip to Content

Generic Doryx MPC Availability

See also: Generic Doryx

Doryx MPC is a brand name of doxycycline, approved by the FDA in the following formulation(s):

DORYX MPC (doxycycline hyclate - tablet, delayed release;oral)

  • Manufacturer: MAYNE PHARMA
    Approval date: May 20, 2016
    Strength(s): EQ 60MG BASE, EQ 120MG BASE

Has a generic version of Doryx MPC been approved?

An Authorized Generic version of Doryx MPC has been approved. An Authorized Generic is a prescription drug that is produced by a brand company under a New Drug Application (NDA) and marketed as a generic under a private label. It is identical to the branded product in appearance, and unlike a generic, the Authorized Generic has exactly the same inactive ingredients.

List of authorized generic versions:

  • Doxycycline Hyclate ORAL TABLET, DELAYED RELEASE 50 mg
    Mayne Pharma
    NDC Code: 518620709
  • Doxycycline Hyclate ORAL TABLET, DELAYED RELEASE 100 mg
    Mayne Pharma Inc.
    NDC Code: 683080710
  • Doxycycline Hyclate ORAL TABLET, DELAYED RELEASE 150 mg
    Mayne Pharma Inc.
    NDC Code: 683080715
  • Doxycycline Hyclate ORAL TABLET, DELAYED RELEASE 200 mg
    Mayne Pharma Inc.
    NDC Code: 683080716
  • Doxycycline Hyclate ORAL TABLET, DELAYED RELEASE 75 mg
    Mayne Pharma Inc.
    NDC Code: 683080775

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Doryx MPC. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Modified release coated drug preparation
    Patent 6,958,161
    Issued: October 25, 2005
    Inventor(s): Hayes; David & LoPore; Angelo & Lukas; Stefan & Quinn; Eugene
    Assignee(s): F H Faulding & Co Limited
    A modified release preparation having one or more coated core elements, each core element including an active ingredient and having a modified release coating, wherein a stabilising coat is provided between each core element and its modified release coating so that, upon in vitro dissolution testing, the amount of active ingredient released at any time on a post-storage dissolution profile is within 40 percentage points of the amount of active ingredient released at any time on a pre-storage dissolution profile.
    Patent expiration dates:
    • December 15, 2022
      ✓ 
      Patent use: TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET
      ✓ 
      Drug product
  • Tabletting process
    Patent 8,715,724
    Issued: May 6, 2014
    Assignee(s): Mayne Pharma International Pty Ltd
    A process for producing a compressed solid dosage form containing an active ingredient. The process includes a step of preparing core elements containing the active ingredient. Optionally the core elements are coated with a pharmaceutically acceptable coating layer to form coated pellets. The core elements or pellets are treated with an anti-static agent and compressed with suitable excipients to form the compressed solid dosage form. Preferred anti static agents are starch, microcrystalline cellulose, kaolin, bentonite, silicates, silicon dioxide, cellulose, stearic acid, sodium stearyl fumarate and glyceryl behenate.
    Patent expiration dates:
    • February 3, 2028
      ✓ 
      Drug product
  • Controlled release doxycycline
    Patent 9,295,652
    Issued: March 29, 2016
    Assignee(s): Mayne Pharma International Pty. Ltd.
    The disclosure provides controlled release compositions comprising tetracyclines and in some embodiments, doxycycline. The controlled release doxycycline compositions of the invention exhibit a superior dissolution profile and provide reduce side effects such as nausea and irritation.
    Patent expiration dates:
    • October 23, 2034
      ✓ 
      Patent use: TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET
      ✓ 
      Drug product
  • Controlled release doxycycline
    Patent 9,446,057
    Issued: September 20, 2016
    Assignee(s): Mayne Pharma International Pty. Ltd.
    The disclosure provides controlled release compositions comprising tetracyclines and in some embodiments, doxycycline. The controlled release doxycycline compositions of the invention exhibit a superior dissolution profile and provide reduce side effects such as nausea and irritation.
    Patent expiration dates:
    • December 23, 2034
      ✓ 
      Patent use: TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
Hide